ClinicalTrials.gg

Program

SPN-817

A development code.

Its studies are mostly in Seizures · Epilepsy, led by Supernus Pharmaceuticals.

Furthest: phase 2, since Aug 23, 20223 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Supernus Pharmaceuticals33 open or runningphase 2since Aug 23, 2022Aug 23, 2022Aug 2027phase 2 · NCT06798896

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 23, 2022First study: phase 2 study in EpilepsyFirst studyNCT05518578 · 60 planned · United States, Australia
  2. Jan 16, 2025Phase 2 study in SeizuresNCT06798896 · 216 planned · United States, Australia, Bulgaria and more
  3. Aug 19, 2025Phase 2 study in SeizuresNCT07141329 · 100 planned · United States, Australia

Ahead

  1. Aug 2027Primary completion: phase 2 study in SeizuresNCT06798896
  2. Dec 31, 2027Primary completion: phase 2 study in SeizuresNCT07141329
  3. Dec 31, 2027Primary completion: phase 2 study in EpilepsyNCT05518578

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07141329Seizures · United States, Australia2By invitationDec 31, 2027100
NCT06798896Seizures · United States, Australia, Bulgaria and more2RecruitingAug 2027216
NCT05518578Epilepsy · United States, Australia2RecruitingDec 31, 202760

How it is read

Names in the registry

  • “SPN-817”, 3 entries

Codes read as this program: SPN817.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.